Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped A lack of efficacy was seen with RO7049665 in a study of ulcerative colitis. This reduces the likelihood that the drug is effective in autoimmune hepatitis.

Conditions

Autoimmune Hepatitis
Autoimmune Chronic Hepatitis

Interventions

DRUG: RO7049665
OTHER: Placebo

Sponsor

Hoffmann-La Roche